Tolcapone could not effectively inhibit the infection against VSV-G pseudovirus and HIV-1 pseudoviruses at concentrations below 100 μM (Figure 7E), which suggested that tolcapone might be an EBOV entry inhibitor that targets EBOV envelope proteins specifically. The gene discussed is ERVW-1; the disease is infection.